Families, survivors, researchers and advocates from across the country gather in Washington, D.C., Sept. 18–20 for CureFest 2026—an annual event dedicated to raising awareness of childhood cancer and amplifying the voices of those affected by it.
Among this year’s featured programs is State of Sarcoma, an opportunity for families and advocates to hear directly from leading experts about where pediatric and adolescent and young adult (AYA) sarcoma research stands—and where it is headed.
Alex Huang, MD, PhD, co-leader of Case CCC's Immune Oncology Program and a physician-scientist University Hospitals Rainbow Babies & Children’s Hospital, is a panelist. A pioneer in immunotherapy for pediatric and AYA sarcomas, Huang’s work includes a first-in-human cell therapy for recurrent Ewing sarcoma.
Designed as an open, accessible conversation rather than a traditional scientific presentation, State of Sarcoma gives families the opportunity to hear candidly from researchers about progress, persistent challenges and promising directions in rhabdomyosarcoma, osteosarcoma, Ewing sarcoma and other pediatric sarcomas. Families can meet one-on-one with researchers following the discussion.
The program is free, but advance registration is requested for each adult attending.